AstraZeneca Gets Imfinzi Boost From CASPIAN Lung Cancer Trial
Prospects for AstraZeneca’s PD-L1 inhibitor Imfinzi received a welcome boost from an interim analysis of the Phase III study in first-line small-cell lung cancer.
You may also be interested in...
Tagrisso, Lynparza and Imfinzi are enjoying stellar sales growth which is unlikely to slow down any time soon.
BMS's Phase III Checkmate-451 combo trial with Opdivo and Yervoy misses its endpoint for small cell lung cancer in overall survival, building on recent disappointment caused by the failure of Checkmate-331.
While the failure of AstraZeneca's Imfinzi in the MYSTIC trial for stage IV lung cancer is a blow, it is not going to have much of an effect on the potential for the company which has carved out a sizeable niche for the drug in stage III NSCLC.